Evidence map›Paper›PMID 41627639›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026

Giant thick melanomas: a retrospective case series.

Marina de la Puente Alonso, Belén Rodríguez Sánchez, Luis Ángel Zamarro Díaz, Jorge Martín-Nieto González, José Antonio Avilés Izquierdo

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Marina de la Puente AlonsoDepartment of Dermatology, Hospital General Universitario Gregorio Marañón, C. del Dr. Esquerdo 46, Retiro, 28007, Madrid, Spain. marinadelapuentealonso@gmail.com.ORCID http://orcid.org/0009-0005-1868-2497
Belén Rodríguez SánchezDepartment of Dermatology, Hospital General Universitario Gregorio Marañón, C. del Dr. Esquerdo 46, Retiro, 28007, Madrid, Spain.
Luis Ángel Zamarro DíazDepartment of Dermatology, Hospital General Universitario Gregorio Marañón, C. del Dr. Esquerdo 46, Retiro, 28007, Madrid, Spain.
Jorge Martín-Nieto GonzálezDepartment of Dermatology, Hospital General Universitario Gregorio Marañón, C. del Dr. Esquerdo 46, Retiro, 28007, Madrid, Spain.
José Antonio Avilés IzquierdoDepartment of Dermatology, Hospital General Universitario Gregorio Marañón, C. del Dr. Esquerdo 46, Retiro, 28007, Madrid, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeGiant thick melanomas (GTMs) are rare tumors characterized by extreme size and depth. We aimed to describe their clinical features and outcomes. METHODS/PATIENTS: We retrospectively reviewed eleven patients diagnosed with GTMs at a tertiary dermatology center. GTMs were defined as primary cutaneous melanomas with diameter > 5 cm and Breslow thickness > 4 mm. Tumor size was measured clinically, and all histopathology was reviewed by two dermatopathologists. Clinical, pathological, treatment, and outcome data were extracted from electronic records.

resultsEleven patients (median age 69 years) presented with large tumors (median diameter 55 mm; median Breslow thickness 12 mm), most often on the trunk or extremities. Over half (54.5%) had stage III-IV disease at diagnosis, and treatments included surgery and systemic therapy. Median overall survival was 13 months, with two long-term survivors.

conclusionsGTMs are aggressive and frequently diagnosed at advanced stages. Early recognition and multidisciplinary management are essential. Giant thick melanoma (GTM) is a rare entity characterized by aggressive behavior and poor prognosis. We conducted a retrospective descriptive study defining GTM as lesions with a diameter > 5 cm and Breslow thickness > 4 mm. Eleven cases were analyzed (mean age: 68.5 years), with a female predominance and predominant localization on the trunk. The main reasons for consultation were tumor growth, bleeding, and neurological symptoms. At diagnosis, AJCC stages ranged from IIB to IV. During follow-up, seven patients died -five due to melanoma and two from other causes-, while two remain alive and under active follow-up. Median follow-up was 1 year (range 0-15 years; mean 3.5 years). These findings confirm the severity of GTM and highlight the persistence of diagnostic delay. The main limitation of this study is the small sample size.

Indexed as

MelanomaSkin NeoplasmsAgedAged, 80 and overFemaleHumansMaleMiddle AgedNeoplasm StagingPrognosisRetrospective StudiesTumor BurdenBreslow thicknessGiant malignant melanomaImmunotherapyMalignant melanomaOncologyReconstructive surgery

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.